Dronabinol

MOORESVILLE, N.C, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The Hemp Doctor has introduced a newly formulated Nighttime “Extended Release” Full Spectrum Gummies, available exclusively at thehempdoctor.com, thdwholesale.com, and their physical store locations. The new blend consists of 50% nano-emulsified cannabinoids combined with 50% of their original long-lasting nighttime gummies formula. Robert Shade, the founder of The Hemp Doctor, explains how the gummies work through a two-phase action. “Once the nano-emulsified cannabinoids are active and communicating with the bodies’ CB1 and CB2 receptors, the distillate-infused portion of the gummy is just starting to kick in, approximately 60-90 minutes later. The full activation happens in two to three hours. So, while you’re feeling the rapid onset within 15-45 minutes, the distillate portion still hasn’t kicked in. It’s a perfect blend, giving you the best of both worlds.” Quicker Onset of Effects and a Longer Duration of Action Say goodbye to restless nights with the Nighttime Extended Release Full Spectrum Gummies. Formulated to provide the ultimate nighttime experience, these gummies are designed to help you fall asleep faster and stay asleep longer. Faster Onset: Effects are felt within 15-45 minutes.Extended Duration: Benefits last two to three hours, ensuring uninterrupted sleep cycles. Packed with 7.5mg Delta 9 THC, 10mg CBN, and 10mg CBD, this powerful blend promotes relaxation and supports sleep cycles. It’s available in Tangerine, Berry Blast, and Cherry Lime flavors, with each jar containing 30 counts of gummies. A 2-count packet is also available for those interested in a sample-sized option. Summary of Key Features and Benefits of the All-New Nighttime Gummies: Dual-action formulation combining rapid onset and extended-release technology.The onset of effects is approximately 15 to 45 minutes, lasting two to three hours.Balanced inclusion of Delta 9 THC, CBD, and CBN.Available in three mouthwatering options.900mg of cannabinoids per jar in total, with each gummy containing 30mg.Certificate of Analysis link available. Building on the success of their widely popular Delta 9 gummies collection, the Nighttime Extended Release Gummies is just one of the many The Hemp Doctor offerings. About The Hemp Doctor The Hemp Doctor has been providing high-quality hemp-derived products in its online shop and brick-and-mortar stores since 2018. The North Carolina-based company is known for offering cannabinoid products ranging from THCA flower to pre-rolls, concentrates, gummies, edibles, vapes, tinctures, and more. What distinguishes The Hemp Doctor is its dedication to quality products and customer satisfaction. With over 100,000 satisfied returning customers, thousands of subscribers, and a Trustpilot rating of 4.6 out of 5 based on 3,730 genuine reviews, The Hemp Doctor has positioned itself as a leader in the industry. As a company strictly adhering to lawful and safe human consumption, The Hemp Doctor’s array of products undergoes third-party DEA-certified lab testing. For media inquiries, interviews, or additional information, please contact: Tara Phoenix tara@thehempdoctor.com +1 917-797-8347 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1de93b75-d466-41a5-b2d5-a09bcf5c2f36

SYDNEY, Australia, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, is pleased to announce the final results of a new scientific study their team has supported titled, "Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)." This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days. From 2016 to 2022, 147 participants were recruited. The study found that the cannabis extract significantly improved the rate of complete response—meaning no vomiting or use of additional medications—from 8% with placebo to 24% with THC: CBD. Other benefits included reduced nausea and fewer daily vomits. However, some side effects were noted, such as sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%). Denise Faltischek, Chief Strategy Officer, and Head of International at Tilray Brands, said, “These findings are encouraging for cancer patients undergoing chemotherapy. This study is a crucial step in improving patient care and quality of life.” She continued, "Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV." Tilray Medical continues to transform lives by providing access to medical cannabis. Tilray is a leading provider of EU-GMP-certified medical cannabis products in over 20 countries. The company has supported medical trials globally, studying cannabis for various conditions, including pediatric epilepsy, cancer-induced nausea, and PTSD. About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents. For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand. About Tilray BrandsTilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. Forward-Looking StatementsCertain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information:Tilray Brands: news@tilray.comInvestors: investors@tilray.com